

Kluwer Patent Blog

United Kingdom: GSK v Wyeth, High Court of Justice of England and Wales, Chancery Division, Patents Court, HP-2015-000002, 12 May 2016

Claire Phipps-Jones (Bristows) · Thursday, March 9th, 2017

The UK Patents Court upheld the validity of Wyeth's patent EP(UK) 2,343,308 relating to a combination product comprising a 2086 protein and a PorA protein used in meningitis B vaccines, rejecting GSK's allegations of lack of entitlement to two of the claimed priority dates, lack of novelty, obviousness (both conventional and so-called "AgrEvo" obviousness), insufficiency and added matter. The court also held that a number of the claims were infringed by GSK's meningitis B vaccine, Bexsero.

A [full summary](#) of this case has been published on [Kluwer IP Law](#).

To make sure you do not miss out on regular updates from the Kluwer Patent Blog, please subscribe [here](#).



Want to improve your IP strategy?

- Manual of Industrial Property
- IP Analytics
- Visser - Annotated European Patent Convention

230+ jurisdictions
36,000+ cases
100+ books
600+ IP law professionals as authors

Request a free demo now
KluwerIPLaw.com

Wolters Kluwer

This entry was posted on Thursday, March 9th, 2017 at 11:51 am and is filed under [Case Law](#), [United Kingdom](#)

You can follow any responses to this entry through the [Comments \(RSS\)](#) feed. Both

comments and pings are currently closed.